Short-Term Changes in Skeletal Muscle Mass After Anthracycline Administration in Adolescent and Young Adult Sarcoma Patients.
Savannah Victoria WootenMichael RothJohn Andrew LivingstonMichelle A T HildebrandtJoya ChandraBehrang AminiEugenie S KleinermanSusan C GilchristPublished in: Journal of adolescent and young adult oncology (2021)
Identification of anthracycline-induced muscle loss is critical for maintaining health in adolescent and young adult (AYA) cancer patients. We used routine chest computed tomography (CT) scans to investigate changes in skeletal muscle of 16 AYA sarcoma patients at thoracic vertebrae 4 (T4) after anthracycline treatment. CT images were examined at three time points (prechemotherapy, postchemotherapy, and 1 year). Significant changes in total skeletal muscle index and density were seen after chemotherapy (p = 0.021 and p = 0.016, respectively) and at 1 year versus baseline (both p < 0.05). This study supports the use of T4 as an early indicator of skeletal muscle loss in AYAs.
Keyphrases
- skeletal muscle
- young adults
- computed tomography
- dual energy
- insulin resistance
- contrast enhanced
- image quality
- mental health
- positron emission tomography
- end stage renal disease
- childhood cancer
- ejection fraction
- healthcare
- magnetic resonance imaging
- newly diagnosed
- chronic kidney disease
- public health
- spinal cord
- prognostic factors
- squamous cell carcinoma
- oxidative stress
- deep learning
- clinical practice
- risk assessment
- type diabetes
- machine learning
- social media
- metabolic syndrome
- optical coherence tomography
- endothelial cells